CAPLIN POINT LABORATORIES
|
CAPLIN POINT LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 60.18 | 49.57 | 39.56 | 32.03 | 28.42 |
| CEPS(Rs) | 67.79 | 55.60 | 46.88 | 38.12 | 32.61 |
| DPS(Rs) | 5.00 | 4.50 | 4.00 | 3.00 | 2.50 |
| Book NAV/Share(Rs) | 293.21 | 235.91 | 183.89 | 144.94 | 114.21 |
| Tax Rate(%) | 18.25 | 16.48 | 20.05 | 19.83 | 20.18 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 32.55 | 30.03 | 31.08 | 30.55 | 30.13 |
| EBIT Margin(%) | 33.36 | 30.83 | 30.45 | 29.70 | 31.25 |
| Pre Tax Margin(%) | 33.32 | 30.77 | 30.39 | 29.55 | 31.22 |
| PAT Margin (%) | 27.24 | 25.70 | 24.30 | 23.69 | 24.92 |
| Cash Profit Margin (%) | 30.39 | 28.77 | 27.99 | 27.17 | 28.58 |
| Performance Ratios | |||||
| ROA(%) | 18.98 | 19.30 | 19.94 | 20.20 | 23.02 |
| ROE(%) | 22.97 | 23.68 | 24.77 | 25.65 | 29.58 |
| ROCE(%) | 26.92 | 26.85 | 28.77 | 28.82 | 33.35 |
| Asset Turnover(x) | 0.70 | 0.75 | 0.82 | 0.85 | 0.92 |
| Sales/Fixed Asset(x) | 2.86 | 3.17 | 2.92 | 2.73 | 2.76 |
| Working Capital/Sales(x) | 1.08 | 1.14 | 1.16 | 1.22 | 1.27 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.35 | 0.32 | 0.34 | 0.37 | 0.36 |
| Receivable days | 100.92 | 88.48 | 85.74 | 87.41 | 82.19 |
| Inventory Days | 70.16 | 64.15 | 58.42 | 71.75 | 58.28 |
| Payable days | 91.22 | 84.89 | 80.02 | 59.05 | 55.04 |
| Valuation Parameters | |||||
| PER(x) | 21.89 | 12.04 | 17.19 | 12.62 | 9.93 |
| PCE(x) | 19.43 | 10.73 | 14.50 | 10.60 | 8.66 |
| Price/Book(x) | 4.49 | 2.53 | 3.70 | 2.79 | 2.47 |
| Yield(%) | 0.38 | 0.75 | 0.59 | 0.74 | 0.89 |
| EV/Net Sales(x) | 5.62 | 2.80 | 3.75 | 2.55 | 2.34 |
| EV/Core EBITDA(x) | 15.41 | 8.28 | 11.00 | 7.70 | 6.71 |
| EV/EBIT(x) | 16.86 | 9.10 | 12.33 | 8.60 | 7.50 |
| EV/CE(x) | 4.11 | 2.18 | 2.75 | 1.99 | 1.80 |
| M Cap / Sales | 5.91 | 3.09 | 4.06 | 2.88 | 2.47 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 15.50 | 15.54 | 19.61 | 22.95 | 33.07 |
| Core EBITDA Growth(%) | 24.41 | 14.68 | 23.07 | 16.85 | 20.14 |
| EBIT Growth(%) | 25.01 | 16.97 | 22.62 | 16.84 | 18.61 |
| PAT Growth(%) | 22.40 | 22.22 | 22.68 | 16.90 | 21.82 |
| EPS Growth(%) | 21.40 | 25.32 | 23.52 | 12.67 | 21.76 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | 0.01 | 0.04 |
| Current Ratio(x) | 5.71 | 5.79 | 6.25 | 7.10 | 5.70 |
| Quick Ratio(x) | 4.62 | 4.72 | 5.15 | 5.85 | 4.05 |
| Interest Cover(x) | 724.63 | 579.65 | 552.17 | 198.25 | 843.86 |
| Total Debt/Mcap(x) | - | - | - | 0.01 | 0.02 |
Compare Financial Ratios of peers of CAPLIN POINT LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CAPLIN POINT LABORATORIES | ₹18,217.6 Cr | 0.2% | 13.4% | 84.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹441,838.0 Cr | 1% | 4.6% | 47.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹156,107.0 Cr | 1% | -3.2% | 59.3% | Stock Analytics | |
| CIPLA | ₹120,270.0 Cr | -1.1% | -0.3% | 20.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹113,077.0 Cr | 2.2% | 12.1% | 21.6% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹96,553.2 Cr | -2.7% | 0.8% | 43.8% | Stock Analytics | |
CAPLIN POINT LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CAPLIN POINT LABORATORIES | 0.2% |
13.4% |
84.1% |
| SENSEX | -2.1% |
-2% |
11.3% |
You may also like the below Video Courses
